These include anti-EGFR monoclonal antibodies for KRAS wild type disease, combinations of anti-EGFR monoclonal antibodies with BRAF inhibitors for BRAF mutant cancers, anti-HER2 therapies for HER2 altered cancers and immune checkpoint inhibitors for microsatellite instability (MSI) high cancers. This evidence concerns the gene BRAF and cancer.